Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Envestnet Portfolio Solutions Inc.

Envestnet Portfolio Solutions Inc. trimmed its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 8.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,509 shares of the medical equipment provider’s stock after selling 403 shares during the period. Envestnet Portfolio Solutions Inc.’s holdings in Lantheus were worth $403,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of LNTH. Quest Partners LLC raised its holdings in Lantheus by 27,685.7% during the third quarter. Quest Partners LLC now owns 1,945 shares of the medical equipment provider’s stock worth $213,000 after purchasing an additional 1,938 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in shares of Lantheus by 16.6% in the 3rd quarter. PNC Financial Services Group Inc. now owns 9,021 shares of the medical equipment provider’s stock worth $990,000 after buying an additional 1,286 shares in the last quarter. Cerity Partners LLC lifted its holdings in shares of Lantheus by 19.8% in the third quarter. Cerity Partners LLC now owns 11,897 shares of the medical equipment provider’s stock valued at $1,306,000 after buying an additional 1,966 shares during the period. Penserra Capital Management LLC bought a new position in Lantheus during the third quarter valued at about $1,331,000. Finally, Centaurus Financial Inc. grew its holdings in Lantheus by 13.0% during the third quarter. Centaurus Financial Inc. now owns 3,103 shares of the medical equipment provider’s stock worth $341,000 after acquiring an additional 357 shares during the period. 99.06% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. The Goldman Sachs Group began coverage on shares of Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective for the company. B. Riley decreased their price target on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research report on Friday, March 21st. Truist Financial increased their price objective on Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. Finally, JMP Securities restated a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, Lantheus presently has an average rating of “Moderate Buy” and an average target price of $129.43.

Insiders Place Their Bets

In related news, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the transaction, the chief financial officer now owns 113,860 shares of the company’s stock, valued at approximately $11,445,207.20. This trade represents a 8.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares of the company’s stock, valued at $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 64,109 shares of company stock worth $6,110,806 in the last quarter. 1.50% of the stock is currently owned by corporate insiders.

Lantheus Stock Down 1.3 %

LNTH opened at $98.43 on Thursday. The firm has a market capitalization of $6.74 billion, a P/E ratio of 16.38 and a beta of 0.38. The stock has a fifty day moving average of $93.01 and a 200-day moving average of $96.47. Lantheus Holdings, Inc. has a 12-month low of $58.16 and a 12-month high of $126.89.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The business had revenue of $391.11 million during the quarter, compared to analysts’ expectations of $376.61 million. On average, analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.